PTEN and cancer: Currently, drugs (BKM120, AZD-5363 and Olaparib) targeting Class IA PI3K, AKT/p70S6K/PKA or PARP have been used in treating patients with PTEN-defective cancers such as hematologic malignancies, pancreatic and colorectal cancers, which are already tested in phase I to phase III clinical trials (151).